Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2015 16:04 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Corp. Reports Third Quarter 2015 Financial Results and Provides Corporate Update

Record PROCYSBI® Product Sales of $25.8 Million Raptor Raises 2015 PROCYSBI Revenue Guidance to $90-$95 Million Company to Host Conference Call and Webcast Today at 4:30 p.m. EST NOVATO,...
October 29, 2015 16:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Hold Third Quarter 2015 Financial Results Conference Call and Webcast on Thursday, November 5, 2015, at 4:30 p.m. ET

NOVATO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2015 financial results on Thursday, November 5,...
October 05, 2015 07:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Completes Acquisition of Quinsair(TM)

NOVATO, Calif., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has completed the acquisition of Quinsair™ (levofloxacin inhalation solution)...
September 23, 2015 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable

NOVATO, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference: Julie Anne Smith,...
September 14, 2015 07:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis

NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of...
August 20, 2015 17:16 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM)

First Inhaled Fluoroquinolone Therapy for Patients with Cystic Fibrosis Approval Received in the European Union and Canada Expansion of Pipeline with Multiple Late-Stage Orphan Indication...
August 20, 2015 14:46 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Voted a "Best Places to Work" Company in the North San Francisco Bay Area

NOVATO, Calif., Aug. 20, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced today that it was named among the top workplaces in the North Bay in the 10th Annual North Bay...
August 17, 2015 07:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Receives FDA Approval of Expanded Label for PROCYSBI(R) to Treat Children Aged 2-6 Years With Nephropathic Cystinosis

NOVATO, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced that the U.S. Food and Drug Administration (FDA) approved the expanded use of PROCYSBI®...
August 06, 2015 16:04 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Corp. Reports Second Quarter 2015 Financial Results and Provides Corporate Update

PROCYSBI® Product Sales Increased 43% Year over Year to $23.3 Million in Second Quarter Balance Sheet Strengthened with over $220 Million in Cash, Cash Equivalents and Short-Term Investments...
July 30, 2015 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Hold Second Quarter 2015 Financial Results Conference Call and Webcast on Thursday, August 6, 2015, at 4:30 p.m. EDT

NOVATO, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2015 financial results on Thursday, August 6,...